- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Proqr Therapeutics N.V.
Industry Sector: HealthTechnology
CEO: Daniel Anton de Boer
Number Of Employees: 156.6
Enterprise Value: $50,831,315
PE Ratio: -5.41
Exchange/Ticker 1: NASDAQ:PRQR
Exchange/Ticker 2: N/A
Latest Market Cap: $179,574,992
BioCentury | Dec 12, 2024
Management Tracks
Two more C-suite hires at Xaira
Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus
BioCentury | Oct 25, 2024
Finance
Septerna’s GPCRs draw strong demand in $288M IPO
BioCentury’s Financial Report: ProQR’s $75M raise, Seaport’s $225M series B and more
BioCentury | Oct 22, 2024
Finance
Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast
What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave
BioCentury | Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
BioCentury | Jan 13, 2023
Finance
4Q22 Wrap: Stopping the bleeding
Winners, losers across biotech market cap tiers in 4Q22
BioCentury | Dec 23, 2022
Deals
Dec. 22 Quick Takes: Mersana picks Merck KGaA for its third ADC deal of 2022
Plus: Lilly builds on genetic medicine focus with ProQR deal and Stifel buying Torreya; Gilead; lecanemab; ORIC-Pfizer and more
BioCentury | Jun 2, 2022
Management Tracks
Anderson to lead Pfizer’s vaccine R&D
Plus CFO Luca Scavo resigns from Evelo, Passage Bio’s CEO steps down, and updates from MindMaze, Black Diamond and more
BioCentury | May 26, 2022
Management Tracks
Zai, BMS veteran Fu joins Frazier as partner
Plus OrbiMed alum Khuong joins Catalio Capital, Warma named CEO of Genexine and more
BioCentury | Feb 23, 2022
Product Development
Lilly aims for technology synergies with unified genetic medicines group
The Lilly Institute for Genetic Medicine brings DNA, RNA therapies under one group — and it’s seeking delivery deals
BioCentury | Feb 12, 2022
Product Development
Challenging rare eye indication sinks a second modality
ProQR’s sepofarsen, an antisense oligonucleotides, stumbles in late-stage trial for LCA10
Items per page:
1 - 10 of 58